Actively Recruiting
Phase II Randomized Study of Topical Mesenchymal Stromal Cell Secretome Eye Drops for Persistent Corneal Epithelial Defects
Led by University of Illinois Chicago · Updated on 2026-10-28
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of topical mesenchymal stromal cell secretome eye drops in adults with persistent corneal epithelial defects that have not improved with standard treatments for at least two weeks. This phase II randomized, double-masked clinical trial compares the secretome eye drops to a vehicle control in patients with chronic corneal epithelial disease or persistent defects. Participants will receive either the investigational mesenchymal stromal cell secretome eye drops or placebo vehicle control for 8 weeks. The treatment is applied topically to the affected eye, with one eye per participant enrolled based on severity. The study includes continued follow-up assessments up to 70 days from the start of treatment to monitor the effects. During the study, participants will undergo various eye evaluations including corneal epithelial barrier integrity, visual acuity, corneal staining with NEI grading, ocular surface parameters, epithelial thickness, symptoms, time to epithelial healing, corneal opacities, vascularization, conjunctival injection, and nerve density. Safety and efficacy will be monitored through these measures, with a total participation duration of approximately 10 weeks from treatment start to final follow-up.
CONDITIONS
Brief Title
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Research Team
A
Ali R Djalilian, MD
C
Charlotte E Joslin, OD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here